Innate Pharma S.A.
IPHYF · Other OTC · USD
1,509USD
0,00 (0,00 %)Stand 11. Nov., 21:00
Kennzahlen
- Eröffnung
- 2,18
- Vortag
- 1,509
- Tagesspanne
- 1,509 – 2,25
- 52 Wochen
- 1,37 – 2,25
- Volumen
- 200
- Ø Volumen
- 111
- Börsenwert
- 141,7 Mio. $
- KGV
- -2,7
- Gewinn je Aktie (TTM)
- -1,06
- Dividendenrendite
- 0,0 %
- Beta
- 0,9
- Nächste Zahlen
- 25. März 2027
Finanzen
| EUR | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 2,79 Mio. | 12,62 Mio. | 61,64 Mio. | 49,64 Mio. | 12,11 Mio. |
| Herstellungskosten | 0 | 51,98 Mio. | 56,02 Mio. | 51,66 Mio. | 47 Mio. |
| Bruttogewinn | 2,79 Mio. | 12,62 Mio. | 5,62 Mio. | 6,01 Mio. | −22,3 Mio. |
| Forschung und Entwicklung | 43,6 Mio. | 51,98 Mio. | 56,02 Mio. | 51,66 Mio. | 47 Mio. |
| Vertrieb und Verwaltung | 11 Mio. | 11,93 Mio. | 18,29 Mio. | 14,47 Mio. | 25,52 Mio. |
| Operatives Ergebnis | −53,43 Mio. | −51,58 Mio. | −12,67 Mio. | −57,43 Mio. | −47,83 Mio. |
| EBITDA | −47,35 Mio. | −46,91 Mio. | −7,58 Mio. | −12,28 Mio. | −43,23 Mio. |
| Nettogewinn | −49,16 Mio. | −49,47 Mio. | −7,57 Mio. | −58,1 Mio. | −52,81 Mio. |
| Gewinn je Aktie (verwässert) | -0,55 | -0,61 | -0,09 | -0,73 | -0,57 |
Bewertung
Letzte 12 Monate
- KGV
- -2,7
- Kurs-Umsatz-Verhältnis
- 148,6
- Kurs-Buchwert-Verhältnis
- -3,2
- PEG
- -0,4
- Bruttomarge
- 1.770,3 %
- Operative Marge
- −5.133,3 %
- Nettomarge
- −4.554,3 %
- Verschuldungsgrad
- -0,5
- EV/EBITDA
- -3,2
- Eigenkapitalrendite
- 152,6 %
- Kapitalrendite (ROIC)
- −380,7 %
- Free-Cashflow-Rendite
- −27,7 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 100,0 % | 100,0 % | 9,1 % | 12,1 % | −184,1 % |
| Operative Marge | −1.917,7 % | −408,6 % | −20,6 % | −115,7 % | −394,9 % |
| Nettomarge | −1.764,5 % | −392,0 % | −12,3 % | −117,1 % | −436,0 % |
| KGV | -3,3 | -4,6 | -28,5 | -4,2 | -6,7 |
| Kurs-Umsatz-Verhältnis | 58,7 | 18,0 | 3,5 | 4,9 | 25,1 |
| Kurs-Buchwert-Verhältnis | -7,5 | 25,7 | 4,2 | 4,5 | 2,8 |
| Verschuldungsgrad | -1,0 | 3,5 | 0,8 | 0,8 | 0,4 |
| Liquidität 3. Grades | 1,3 | 2,6 | 3,7 | 3,4 | 1,7 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 158,1 Mio. | 191,59 Mio. | 185,4 Mio. | 201,09 Mio. | 244,78 Mio. |
| EV/EBITDA | -3,3 | -4,1 | -24,5 | -16,4 | -5,7 |
| Eigenkapitalrendite | 226,6 % | −560,0 % | −14,6 % | −107,3 % | −49,2 % |
| Kapitalrendite (ROIC) | −133,9 % | −59,4 % | −8,8 % | −34,1 % | −21,9 % |
| Free-Cashflow-Rendite | −32,3 % | −3,2 % | −16,2 % | −8,3 % | −19,6 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −77,9 % | −79,5 % | +24,2 % | +309,8 % | −82,6 % |
| Bruttogewinn | −77,9 % | +124,6 % | −6,5 % | +127,0 % | −211,1 % |
| Operatives Ergebnis | −3,6 % | −307,1 % | +77,9 % | −20,1 % | −4.532,3 % |
| Nettogewinn | +0,6 % | −553,5 % | +87,0 % | −10,0 % | +17,5 % |
| Gewinn je Aktie | +9,8 % | −577,8 % | +87,7 % | −28,1 % | −5.328,6 % |
| Freier Cashflow | −625,6 % | +79,1 % | −72,2 % | +66,1 % | +5,2 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 3Kaufen
- 0Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 50,3 Mio. | 61,4 Mio. | 109,05 Mio. |
| Umsatz (Tief – Hoch) | 7,22 Mio. – 74,23 Mio. | 7 Mio. – 183,56 Mio. | 13,69 Mio. – 261,6 Mio. |
| Gewinn je Aktie (Ø) | -0,05 | -0,18 | 0,41 |
| Gewinn je Aktie (Tief – Hoch) | -0,15 – 0,01 | -0,52 – 0,03 | -0,06 – 1,16 |
| Analysten | 1 | 1 | 1 |
Letzte Änderungen
- HC Wainwright & Co.17. Sept. 2023Buy
- HC Wainwright & Co.15. Juni 2023Buy
- SVB Leerink14. Nov. 2022Outperform
- Citigroup15. Sept. 2022Buy
- SVB Leerink1. Aug. 2022Outperform
- SVB Leerink10. Mai 2022Outperform
- SVB Leerink16. Sept. 2021Outperform
- SVB Leerink2. Sept. 2021Market Perform → Outperform
Quartalszahlen
Nächste Zahlen: 25. März 2027| Nov. 2026 | März 2026 | Sept. 2025 | Mai 2025 | Nov. 2024 | Mai 2024 | Sept. 2023 | März 2023 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,29 | -0,35 | -0,33 | -0,26 | -0,30 | -0,45 | 0,09 | -0,42 |
| Gewinn je Aktie · Tatsächlich | -0,24 | -0,35 | -0,29 | -0,32 | -0,33 | -0,13 | 0,02 | -0,87 |
| Abweichung | +17,65 % | 0,00 % | +12,36 % | −19,57 % | −9,78 % | +71,53 % | −74,36 % | −107,26 % |
| Umsatz · Tatsächlich | 6,47 Mio. | 4,87 Mio. | 5,72 Mio. | 285.795,24 | 13,27 Mio. | 23,58 Mio. | 43,85 Mio. | 8,95 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
AAWHAscend Wellness Holdings, Inc.0,366−0,27 %
BRIBFBrii Biosciences Limited0,130,00 %
BXPHFBotanix Pharmaceuticals Limited0,00730,00 %
HOFBFHofseth BioCare ASA0,11830,00 %
JWCTFJW (Cayman) Therapeutics Co. Ltd0,20220,00 %
KNTPFKintor Pharmaceutical Limited0,15670,00 %
MLLCFMolecular Partners AG4,010,00 %
NDTPNDT Pharmaceuticals Inc.0,0552+11,07 %
Über das Unternehmen
Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor that has progressed to Phase III clinical trials, being investigated for its potential in treating advanced solid tumors, notably colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1. This compound is in Phase II clinical assessment for a range of inflammatory conditions, including COVID-19, bullous pemphigoid, and chronic spontaneous urticaria. IPH5201: A blocking antibody in Phase I trials, aimed at the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody targeting the immunosuppressive adenosine pathway to enhance anti-tumor immunity. IPH6101: An NKp46-based NK cell engager, intended for the development and assessment of up to two bispecific NK cell engagers. Beyond its clinical programs, Innate Pharma maintains an active preclinical research effort, featuring candidates such as IPH43 (an anti-MICA/B antibody-drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. To support its development and market reach, Innate Pharma has established strategic alliances and licensing agreements with major pharmaceutical companies, including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Additionally, it holds a co-development and license agreement with MedImmune Limited. The company was founded in 1999 and continues to operate from its headquarters in Marseille, France.
Führung
- Jonathan E. DickinsonChief Executive Officer & Director
- Sonia QuaratinoExecutive Vice President & Chief Medical Officer
- Yannis MorelExecutive Vice President & Chief Operating Officer
- Claire de Saint BlanquatVice President of Legal & Corporate Affairs and Secretary of the Supervisory Board
- Odile BelzunceVP, Chief of Compliance & Operations Officer and Interim Head of HR
- François RomagnéFounder
- CEO
- Jonathan E. Dickinson
- Mitarbeitende
- 163
- Hauptsitz
- Marseille, PA, FR
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 9. Juni 2015
- Website
- innate-pharma.com
Nachrichten
- Business Wire · 11. Nov., 1:00Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026
- Business Wire · 5. Nov., 1:00Innate Pharma Reports Third Quarter 2026 Business and Financial Update
- Business Wire · 27. Okt., 2:00Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
- Business Wire · 21. Okt., 1:00Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
- Defense World · 4. Okt., 7:41Innate Pharma (OTCMKTS:IPHYF) Stock Falls 32.9% – Here’s What Happened
- Business Wire · 17. Sept., 1:00Innate Pharma Reports First Half 2026 Business Update and Financial Results
- Business Wire · 14. Aug., 5:30Innate Pharma Announces Conference Call and Webcast
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.